



INTERNATIONAL GENERIC AND  
BIOSIMILAR MEDICINES ASSOCIATION

Info: [info@igbamedicines.org](mailto:info@igbamedicines.org)

## **Vinita Gupta and Lucas Sigman appointed 2024 Chair and Vice-Chair of the IGBA CEO Advisory Committee**

For immediate release

Geneva, 14 December 2023

The [International Generic and Biosimilar medicines Association](https://www.igbamedicines.org) (IGBA) announced today the annual leadership change of its [CEO Advisory Committee](#) (AC). [Vinita Gupta](#), CEO of Lupin, was appointed Chair and [Lucas Sigman](#), CEO of Insud Pharma, Vice-Chair.

The CEO AC is composed of fifteen leading multinational companies from Canada, Europe, India, Israel, Japan and the United States. This Committee provides a forum for industry leaders to discuss broad, strategic issues, and to engage and position the industry on a range of critical policy issues.

*“I look forward to this unique opportunity to drive our industry forward in 2024 and to strengthen it’s collective voice in the global pharmaceutical space”, commented Vinita Gupta, adding “With critical issues related to supply chain, shortages, and regulatory harmonization, there are many opportunities for our industry to contribute to the policy dialogue focused on a more resilient global supply of medicines.”*

Vinita Gupta will succeed [Richard Saynor](#), CEO of Sandoz. *“On behalf of IGBA and all its members, I would like to thank Richard for his important role as the inaugural Chair of our CEO Advisory Committee,”* said David Gaugh, the Chair of IGBA’s Management Committee, adding *“His leadership and unwavering commitment have been instrumental in shaping IGBA’s efforts to promote sustained access to quality-assured generic and biosimilar medicines and expanding our collaboration with organizations like the WHO, WTO and WIPO.”*

*“The generic and biosimilar medicines industry supplies an estimated 80% of all quality-assured medicines globally and is therefore absolutely critical to ensuring safe and affordable medicines are available to patients around the world”,* commented Richard Saynor. *“Together we can ensure that our industry is an integral part of the global health conversation and that generic and biosimilar medicines are central to global healthcare policy discussions,”* Saynor concluded.

### **About IGBA**

The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: [www.igbamedicines.org](https://www.igbamedicines.org).